News | October 12, 2012

Neurosurgeon Mark P. Carol Honored by ASTRO For Contributions to IMRT, IGRT

ASTRO Mark P Carol Radiation Theraphy

October 12, 2012 – The American Society for Radiation Oncology (ASTRO) has named Mark P. Carol, M.D., a distinguished leader in the fields of intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), as its 2012 Honorary Member, which is the highest honor the society bestows upon distinguished cancer researchers and leaders in disciplines other than radiation oncology, radiation physics or radiobiology. Carol will be recognized with this honor during the Awards Ceremony on Tuesday, Oct. 30, 2012, at 10:45 a.m., at ASTRO’s 54th Annual Meeting, Oct. 28 to 31, 2012, at the Boston Convention and Exhibition Center.

With more than 30 years of experience in the medical device and health care services arenas, Carol is often considered the father of IMRT. Since 1992, he has developed and created many novel and crucial devices and techniques that have influenced and shaped modern radiation oncology, such as computed tomography (CT)/ magnetic resonance imaging (MRI) image fusion with ultrasound treatment room-based localization, intensity modulated treatment delivery, DVH-based prescriptions, simulated annealing optimization and image-guided therapy. Most recently, Carol has been developing an innovative way to deliver radiation therapy that uses a multiplexed photon beam to treat patients in sitting and standing positions, thereby reducing overall costs while at the same time allowing advanced multimodality imaging to be introduced seamlessly into the treatment room.

“Throughout the years, Carol, who trained as a neurosurgeon, has been a pioneer and innovator in the field of radiation oncology,” said Michael L. Steinberg, M.D., FASTRO, ASTRO president. “His groundbreaking approach to the development of IMRT and IGRT has provided tremendous benefits for radiation oncology patients. He is most deserving of this year’s honor.”

Serving as a founder, CEO and president for numerous corporations, Carol has constantly proven himself to be a successful innovator within the field of radiation oncology. He was awarded the Pittsburgh Business Times’ Health Care Hero Competition Award and the Ira Sohn Research Conference Prize in Pediatric Oncology from the Gotham Prize for Cancer Research. In 2004, Carol also garnered honorary membership in the American Association of Physicists in Medicine (AAPM).

Carol is a graduate of Amherst College in Amherst, Mass., as an independent scholar, and he graduated with distinction in research from the University of Rochester’s School of Medicine & Dentistry in Rochester, N.Y. At the University of Rochester, Carol worked on developing an artificial heart, for which he now holds a patent. From 1978-1984, he served as a neurosurgical resident and a fellow in neurotraumatology at the University of Maryland in College Park, M.D., and he later went on to practice at the Mary Imogene Bassett Hospital in Cooperstown, N.Y. He has also taught as an assistant professor of neurosurgery at Columbia University in New York, the University of South Florida in Tampa, Fla., and the Medical College of Ohio in Toledo, Ohio. Since 2009, Carol has been an adjunct assistant professor of radiation oncology at Brown University in Providence, R.I. He is currently the chief development officer at U.S. HIFU, an innovator in the use of high intensity focused ultrasound for thermal ablation, based in Charlotte, N.C.

For more information: www.astro.org

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.